# US 2012/0251546 A1 · Type 1 inteferon diagnostic

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251546 A1
- Document ID: US20120251546A1
- Status: Published application
- Kind: A1
- Application number: 13/393,616
- Filed: 2010-09-02
- Published: 2012-10-04
- Earliest claimed: 2009-09-03
- Assignees: MedImmune, LLC
- Inventors: Brandon Higgs; Wei Zhu; Chris Morehouse; Barbara White; Bahija Jallal; Yihong Yao
- Web page: https://patentgrep.com/patent/US20120251546A1

## CPC

- C07K 16/249: {Interferons}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C07K 2317/565: Complementarity determining region [CDR]
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.

## Claims

### Claim 1

A method of identifying a subject suitable for treatment with a therapeutic agent that modulates type 1 interferon activity comprising detecting increased mRNA of at least four of IFI27, IFI44, IFI44L, IFI6, and RSAD2 in a sample of the subject, wherein an increase in mRNA of at least about four fold indicates a subject suitable for treatment with the agent.

### Claim at position 2

2-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the agent is chosen from an anti-interferon alpha antibody and an anti-interferon alpha receptor antibody.

### Claim 8 (depends on 7)

The method of claim 7, wherein the anti-interferon antibody is sifalimumab.

### Claim 9 (depends on 7)

The method of claim 7, wherein the anti-interferon antibody is not sifalimumab.

### Claim 10 (depends on 1)

The method of claim 1 wherein detecting mRNA of at least IFI27, IFI44, IFI44L, IFI6, and RSAD2 comprises
1) isolating RNA from a sample obtained from the subject;
2) synthesizing cDNA from the RNA;
3) hybridizing the cDNA with oligonucleotides that hybridize to nucleic acid sequences of SEQ ID NOs: 25-32; and
4) amplifying the cDNA and detecting the amplified products.

### Claim 11 (depends on 10)

The method of claim 10, wherein the oligonucleotides are chosen from oligonucleotides having the sequences of SEQ ID NOs: 13-24.

### Claim 12

A method of identifying a subject suitable for treatment with a therapeutic agent that modulates type 1 interferon activity comprising detecting increased mRNA of at least four of IFI27, IFI44, IFI44L, IFI6, and RSAD2 in a sample of the subject, wherein the increased mRNA is calculated according to the following algorithm:
Δ


Ct
IFN
=
(
Ct
IFI


44
-
Ct
REF
)
+
(
Ct
IFI


44

L
-
Ct
REF
)
+
(
Ct
IFI


27
-
Ct
REF
)
+
(
Ct
RSAD


2
-
Ct
REF
)
4
;
wherein
Δ


Ct
REF
=
Ct
ACTB
+
Ct
GAPDH
+
Ct
18

S
3
and wherein a ΔCtIFN of about 7.6 indicates a subject suitable for treatment with the agent.

### Claim 13 (depends on 12)

The method of claim 12, wherein the agent is chosen from an anti-interferon alpha antibody and anti-interferon alpha receptor antibody.

### Claim 14 (depends on 13)

The method of claim 13, wherein the anti-interferon antibody is sifalimumab.

### Claim 15 (depends on 13)

The method of claim 13, wherein the anti-interferon antibody is not sifalimumab.

### Claim 16 (depends on 12)

The method of claim 12, wherein detecting the mRNA of at least IFI27, IFI44, IFI44L, IFI6, and RSAD2 comprises:
1) isolating RNA from a sample obtained from the subject;
2) synthesizing cDNA from the RNA
3) hybridizing the cDNA with oligonucleotides that hybridize to nucleic acid sequences of SEQ ID NOs: 25-35, and
4) amplifying the cDNA and detecting the amplified products.

### Claim 17 (depends on 16)

The method of claim 16, wherein the oligonucleotides are chosen from oligonucleotides having the sequences of SEQ ID NOs: 1-24.

### Claim 18

A method for treating a subject with a therapeutic agent that modulates type 1 interferon activity comprising:
a) identifying a subject suitable for treatment by detecting increased mRNA of at least four of IFI27, IFI44, IFI44L, IFI6, and RSAD2 in a sample of the subject, wherein an increase in mRNA of at least about 4 fold indicates a subject suitable for treatment; and
b) administering the therapeutic agent.

### Claim at position 15

19-22. (canceled)

### Claim 23 (depends on 18)

The method of claim 18, wherein the agent is chosen from an anti-interferon alpha antibody and anti-interferon alpha receptor antibody.

### Claim 24 (depends on 23)

The method of claim 23, wherein the anti-interferon antibody is sifalimumab.

### Claim 25 (depends on 23)

The method of claim 23, wherein the anti-interferon antibody is not sifalimumab.

### Claim at position 19

26-27. (canceled)

### Claim 28

A method of identifying a subject suitable for treatment with a therapeutic agent that modulates type 1 interferon activity comprising
a) detecting increased mRNA of at least four of IFI27, IFI44, IFI44L, IFI6, and RSAD2 in a sample of the subject, wherein the increased mRNA is calculated according to the following algorithm:
Δ


Ct
IFN
=
(
Ct
IFI


44
-
Ct
REF
)
+
(
Ct
IFI


44

L
-
Ct
REF
)
+
(
Ct
IFI


27
-
Ct
REF
)
+
(
Ct
RSAD


2
-
Ct
REF
)
4
;
wherein
Δ


Ct
REF
=
Ct
ACTB
+
Ct
GAPDH
+
Ct
18

S
3
and wherein a ΔCtIFN of about 7.6 indicates a subject suitable for treatment with a therapeutic agent that modulates IFNα activity; and
b) administering the therapeutic agent.

### Claim 29 (depends on 28)

The method of claim 28, wherein the agent is chosen from an anti-interferon alpha antibody and anti-interferon alpha receptor antibody.

### Claim 30 (depends on 29)

The method of claim 29, wherein the anti-interferon antibody is sifalimumab.

### Claim 31 (depends on 29)

The method of claim 29, wherein the anti-interferon antibody is not sifalimumab.

### Claim at position 24

32-33. (canceled)
